Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib-Based Therapy for Cohesin-Mutated AML and MDS
NCT03974217Phase 1Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2019
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of talazoparib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Proportion of participants with >= 50% leukemic blast reduction at 1 year. Started Aug 2019; status: active, not recruiting.
02
Drugs
talazoparib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03974217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03974217.